Shotaro Haji

Shotaro Haji

Auto-generated profile, based on publicly available information

Shotaro Haji

Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
KIKeiko Imamura
Keiko Imamura
YIYuishin Izumi
Yuishin Izumi
NENaohiro Egawa
Naohiro Egawa
TATakashi Ayaki
Takashi Ayaki
MNMakiko Nagai
Makiko Nagai
HIHaruhisa Inoue
Haruhisa Inoue
Introduction Amyotrophic lateral sclerosis (ALS) is a progressive, severe neurodegenerative disease caused by motor neuron death. Development of a medicine for ALS is urgently needed, and induced pluripotent cell-based drug repurposing identified a Src/c-Abl inhibitor, bosutinib, as a candidate for molecular targeted therapy of ALS. A phase 1 study confirmed the safety and tolerability of bosutinib in a 12-week treatment of ALS patients. The objectives of this study are to evaluate the efficacy and longer-term safety of bosutinib in ALS patients. Methods and analysis An open-label, multicentre phase 2 study was designed. The study consisted of a 12-week observation period, a 1-week transitional period, a 24-week study treatment period and a 4-week follow-up period. Following the transitional period, patients whose total Revised ALS Functional Rating Scale (ALSFRS-R) score declined by 1 to 4 points during the 12-week observation period were to receive bosutinib for 24 weeks. In this study, 25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 12 patients in the 200 mg quaque die (QD) group and 13 patients in the 300 mg QD group of bosutinib. The safety and exploratory efficacy of bosutinib in ALS patients for 24 weeks will be assessed. Efficacy using the ALSFRS-R score will be compared with the external published data from an edaravone study (MCI186-19) and registry data from a multicentre ALS cohort study, the Japanese Consortium for Amyotrophic Lateral Sclerosis Research. Ethics and dissemination This study was approved by the ethics committees of Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University School of Medicine, Toho University and Hiroshima University. The findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial Registration number jRCT2051220002; Pre-results, NCT04744532; Pre-results

30 January 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
SHShotaro Haji
Shotaro Haji
KFKoji Fujita
Koji Fujita
RORyosuke Oki
Ryosuke Oki
YOYusuke Osaki
Yusuke Osaki
RMRyosuke Miyamoto
Ryosuke Miyamoto
YIYuishin Izumi
Yuishin Izumi
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, with its currently approved drugs, including riluzole and edaravone, showing limited therapeutic effects. Therefore, safe and effective drugs are urgently necessary. EPI-589 is an orally available, small-molecule, novel redox-active agent characterized by highly potent protective effects against oxidative stress with high blood-brain barrier permeability. Given the apparent oxidative stress and mitochondrial dysfunction involvement in the pathogenesis of ALS, EPI-589 may hold promise as a therapeutic agent. Objective: This protocol aims to describe the design and rationale for the EPI-589 Early Phase 2 Investigator-Initiated Clinical Trial for ALS (EPIC-ALS). Methods: EPIC-ALS is an explorative, open-labeled, single-arm trial that evaluates the safety and tolerability of EPI-589 in patients with ALS. This trial consists of 12-week run-in, 24-week treatment, and 4-week follow-up periods. Patients will receive 500 mg of EPI-589 3 times daily over the 24-week treatment period. Clinical assessments include the mean monthly change of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised total score. The biomarkers are selected to analyze the effect on oxidative stress and neuronal damage. The plasma biomarkers are 8-hydroxy-2′-deoxyguanosine (8-OHdG), 3-nitrotyrosine (3-NT), neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH), homocysteine, and creatinine. The cerebrospinal fluid biomarkers are 8-OHdG, 3-NT, NfL, pNfH, and ornithine. The magnetic resonance biomarkers are fractional anisotropy in the corticospinal tract and N-acetylaspartate in the primary motor area. Results: This trial began data collection in September 2021 and is expected to be completed in October 2023. Conclusions: This study can provide useful data to understand the characteristics of EPI-589. Trial Registration: Japan Primary Registries Network jRCT2061210031; tinyurl.com/2p84emu6 International Registered Report Identifier (IRRID): DERR1-10.2196/42032

2 July 2024 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SHShotaro Haji
Shotaro Haji
WSWataru Sako
Wataru Sako
HIHaruhisa Inoue
Haruhisa Inoue
YOYusuke Osaki
Yusuke Osaki
YIYuishin Izumi
Yuishin Izumi

13 March 2024 in Heliyon
Verified
Journal Article
Open access
YYYuki Yamamoto
Yuki Yamamoto
KFKoji Fujita
Koji Fujita
HYHiroki Yamazaki
Hiroki Yamazaki
SHShotaro Haji
Shotaro Haji
YOYusuke Osaki
Yusuke Osaki
YIYuishin Izumi
Yuishin Izumi
Constipation has been recently recognized as a complication associated with motor and autonomic dysfunction in patients with motor neuron disease (MND), typified by amyotrophic lateral sclerosis (ALS). However, the long-term characteristics of constipation remain unclear in patients with MND. We longitudinally investigated the prevalence and risk factors of constipation in a consecutive cohort of patients with MND. Data from Japanese patients with MND enrolled in a single-center registry from June 2017 to December 2021 were retrospectively investigated. The diagnosis of ALS was based on the updated Awaji criteria, and other MND subtypes were also included. The presence or absence of constipation symptoms was determined by referring to the Rome III criteria. The clinical backgrounds and symptoms of patients with and without constipation were compared. Among 155 consecutive patients (female, 63; age, 66.5 ± 12.4 years), 30.3% had constipation at diagnosis and 52.9% after a median follow-up of 18 months. Univariate analysis showed that female sex, use of tracheostomy and invasive ventilation, and delivery of enteral nutrition were more frequent in the constipation group. The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale score was significantly lower in the constipation group, especially for the sub-items related to physical motor function. Multivariate analysis showed that the use of enteral nutrition was an independent risk of constipation, with an odds ratio of 3.69 (95% CI, 1.49–9.17; p = 0.005). Constipation had a high prevalence in patients with MND with impaired motor function. Controlling defecation is important in patients with MND, especially during enteral nutrition.

29 May 2025 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
SHShotaro Haji
Shotaro Haji
WSWataru Sako
Wataru Sako
KHKenta Hanada
Kenta Hanada
TMTomoyasu Matsubara
Tomoyasu Matsubara
YOYusuke Osaki
Yusuke Osaki
YIYuishin Izumi
Yuishin Izumi
Background: Iron deposition and atrophy of the subthalamic nucleus (STN) have been reported in progressive supranuclear palsy (PSP). Quantitative susceptibility mapping (QSM), an advanced MRI technique, enables noninvasive assessment of the magnetic susceptibility of biological tissue and has been reported to have good ability to delineate STN. Objective: The aim of this study is to evaluate the diagnostic accuracy of a model using magnetic susceptibility and area of the STN assessed by QSM to differentiate PSP from Parkinson's disease (PD). Methods: A total of 35 patients with PSP and 28 patients with PD were recruited. Magnetic susceptibility and area of the STN were measured by QSM. Axial and coronal scans were acquired to measure the STN magnetic susceptibility and area. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic accuracy for differentiating PSP from PD. Results: In the axial scan group, STN susceptibility was significantly higher in PSP than PD ( p = 0.047), with no difference in the coronal scan group ( p = 0.066). PSP patients had a smaller STN area than PD in both axial ( p < 0.001) and coronal ( p = 0.002) scan groups. The combination of these metrics showed high diagnostic accuracy (Axial, AUC = 0.87; Coronal, AUC = 1.00) and excellent performance (AUC = 0.98) in cases within 3 years of onset. Conclusions: A combination of magnetic susceptibility and area of the STN measured by QSM can be used to discriminate PSP from PD, even at early stages.

15 October 2018 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SHShotaro Haji
Shotaro Haji
FEFutoshi Eto
Futoshi Eto
TTTsuyoshi Torii
Tsuyoshi Torii
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies